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ABSTRACT. The aim of this study was to examine gender differences
in quality of life (QOL) and in constitutional symptoms that coincide
with sarcoidosis. The study population included 1026 sarcoidosis pa-
tients- all members of the Dutch Sarcoidosis Society-who completed
the WHOQOL-100 and a symptom checklist. Women experienced
more symptoms than men. With regard to QOL, male and female pa-
tients who suffered from symptoms differed in the broader domains of
Physical Health and Psychological Health. Specific facets reflected
pain, sleep, positive affect, appearance, mobility, and activities of daily
living. Future studies should focus on the different experience of the
disease between male and female patients more extensively. Studies are
needed to evaluate whether the differences in the present study between
male and female sarcoidosis patients are caused by a subject selection
bias or life style differences; have a genetic, hormonal or biological
base; or just are an epiphenomenon. [Article copies available for a fee from
The Haworth Document Delivery Service:1-800-342-9678. E-mail address:
getinfo@haworthpressinc.com <Website: http://www.haworthpressinc.com>]
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INTRODUCTION
The number of studies into health status and quality of life (QOL) has
increased enormously over the last ten years. The focus of the majority of
these investigations is on the influence of disease on QOL and health status.
Generally, gender is often used only as a covariate (e.g., Matikka & Vesala,
1997; McCann, Russo, Benjamin, & Andrew, 1997) or as one of the charac-
teristics for matching groups (e.g., Conroy, 1996). However, only few studies
focussed on the possible role of gender. Haug and Folmar (1986) studied
QOL in non-institutionalized elderly men and women. Results indicated that
older women received less spousal support and had a substantially lower
income. In addition, compared with males, women suffered more from health
problems and demonstrated more cognitive and emotional losses. In a more
recent study, Norum and Wist (1996) focussed on gender and treatment
modalities in relation to the QOL of survivors of Hodgkin’s disease. In
contrast with expectations, female survivors reported better global QOL and
lower fatigue scores than male survivors. Several reviews described gender
differences in cause-specific mortality and morbidity (e.g., Verbrugge, 1985;
Wingard & Cohn, 1990). For instance, gender differences were studied re-
garding aspects of QOL in cardiac patients (Kinney, Burfitt, Stullenbarger,
Rees, & Debolt, 1996), elderly carers (Draper, Poulos, Poulos, & Ehrlich,
1996), genital herpes patients (Jadack, Keller, & Hyde, 1990), and patients
with mental disorders (Linzer et al., 1996).
Chronic Non-Specific Lung Disease (CNSLD) has shown to have in-
fluenced health status substantially (Maillé, Kaptein, De Haes, & Everaerd,
1996). For example, Schrier, Dekker, Kaptein, and Dijkman (1990) found
that elderly patients with CNSLD experienced substantial problems in the
area of physical as well as psychological functioning and reported more
dysfunction compared to a healthy control group. In accordance with other
studies (e.g., Guyatt, Townsend, Berman, & Pugsley, 1987; Ketelaars et al.,
1996; McSweeny, Grant, Heaton, Adams, & Timms, 1982; Williams & Bury,
1989), Okubadejo, Jones, and Wedzicha (1996) recently reported impairment
in most areas of health status in patients with chronic obstructive pulmonary
disease (COPD). However, gender differences have been given very little
attention. An exception is the study by Isoaho, Keistinen, Laippala, and
Kivela (1995) who found that in female COPD patients, in contrast to males,
the disease was related to disability, feelings of dissatisfaction with life, and
low satisfaction with their marital relationship. In the investigation by Wil-
liams and Bury (1989), male COPD patients reported more problems in the
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area of work, while female COPD patients had more problems in the area of
domestic responsibilities. Finally, research by Leidy and Traver (1995) indi-
cated that somatic symptoms predicted health status in female COPD patients
only.
Sarcoidosis is a disorder of unknown origin most frequently occurring in
the lung. Clinical manifestations of sarcoidosis depend on the intensity of the
inflammation and organ systems affected. Sarcoidosis presents itself in a
variety of ways. It is estimated that about 20% to 50% of the patients have
respiratory symptoms including cough, dyspnea, chest pain, wheezing, and
chest discomfort (Thomas & Hunninghake, 1987). Furthermore, fatigue, ar-
thralgia, and erythema nodosum are common features of sarcoidosis which
show, however, some variation across countries (e.g., Fité et al., 1996; Pieti-
nalho, Ohmichi, Hiraga, Löfroos, & Selroos, 1996; Wirnsberger, De Vries,
Wouters, & Drent, 1998). The disease is probably more common amongst
women, although this also appears to vary from country to country (e.g., Du
Bois, 1995; Hillerdal, Nöu, Osterman, & Schmekel, 1984). The peak inci-
dence of sarcoidosis occurs between the ages 20 and 40 in both men and
women, with a second lower and broader peak in women between 45 and 65
yeas of age (Hillerdal et al., 1984; Klonoff & Kleinhenz, 1993). In The
Netherlands, the prevalence of sarcoidosis is estimated to be 20-30/100,000,
i.e., between 3,200 and 4,800 patients (James, 1992). Only recently several
investigations into the QOL and health status of sarcoidosis patients were
conducted. Drent et al. (1998) demonstrated that sarcoidosis patients were
limited in their physical and psychological functioning. They appeared to be
affected predominantly in the areas of sleep and rest, recreation and pastime,
employment, alertness behaviour, emotional behaviour and social interaction
compared to a control group. With regard to gender differences, female
patients showed more emotional problems as well as body care and move-
ment problems than males. Wirnsberger, De Vries, Breteler et al. (1998)
found that fatigue was a substantial problem in sarcoidosis. Moreover,
compared to the healthy controls, patients with constitutional complaints had
more problems with their mobility, activities of daily living, working capac-
ity and recreation than sarcoidosis patients without any current symptoms.
Furthermore, female sarcoidosis patients reported more sleep problems than
male patients.
As sarcoidosis often resolves spontaneously, therapeutic intervention is
not necessary in all patients (Müller-Quernheim, 1996). There is general
agreement that patients with extra pulmonary manifestations, such as in-
volvement of eyes or heart, should undergo treatment (Du Bois, 1995). More-
over, therapy is indicated with persistent hypercalcaemia (Costabel & Tes-
chler, 1997; Sharma, 1996) or rapid deterioration of pulmonary function tests
(Hunninghake et al., 1994; Newman, Rose, & Maier, 1997). Corticosteroids
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are considered the most effective therapy (Yamamoto, Sharma, & Hosada,
1991). However, corticosteroids have significant side effects (Costabel &
Teschler, 1997) and their effect on long-term outcome of sarcoidosis are
controversial (Eule, Weinecke, & Roth, 1986; Gibson et al., 1996; Gottlieb,
Israel, Steiner, Triolo, & Patrick, 1997). Occasionally, non-steroidal anti-in-
flammatory drugs (NSAIDs) are prescribed to treat minimal disease (Baugh-
man & Lower, 1997). This may relieve arthralgia and muscle pain and have
an anti-inflammatory effect in sarcoidosis.
Differences in reported symptoms between male and female patients have
been studied by, for instance, O’Keefe, Taley, Zinsmeister, and Jacobsen
(1995) who demonstrated that gender differentiated between asymptomatic
and symptomatic groups with bowel disorders. The results of pulmonary
studies are inconsistent. Whilst Sherrill, Lebowitz, Knudson, and Burrows
(1993) and Janson-Bjerklie, Carrieri, and Hudes (1986) reported gender dif-
ferences in disease symptoms, Van den Boom et al. (1998) found no such
differences between COPD patients who did or did not consult their general
practitioners concerning respiratory symptoms. Moreover, gender differences
were also found in married people (Mookherjee, 1997), homeless people
(Ritchey, La Gory, & Mullis, 1991) and with regard to sensitive cough reflex,
in healthy subjects (Dicpinigaitis & Rauf, 1998).
In sarcoidosis, less is known about gender differences in QOL and consti-
tutional symptoms. Additionally, a thorough knowledge of gender differ-
ences in medication prescription is lacking. The aim of this study, therefore,
was to evaluate gender differences with regard to the constitutional symp-
toms, QOL, and medical consumption of sarcoidosis patients.
METHODS
Subjects
All 1,755 members of the Dutch Sarcoidosis Society (DSS) suffering from
sarcoidosis were sent a test-booklet together with a letter from the DSS in
which they were asked to participate in an in-depth study on quality of life
and symptoms. Of the 1,093 patients (62.3%) who responded, 1,026 (58.5%
of the total group) completed the questionnaires. The remaining 67 people
gave a number of reasons why they did not wish to participate in the study.
The main reasons included (i) the innumberable list of questions (14), (ii) a
lack of time (10), (iii) the absence of symptoms (9), and (iv) the fact that the
diagnosis was made quite some time ago. Eight people returned the test-
booklet without giving any reason. Because the DSS does not register the sex
of its members, unfortunately no information on this point is available about
the non-response group.
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Measures
All participants completed the World Health Organization Quality of Life
assessment instrument-100 (WHOQOL-100; Dutch version De Vries & Van
Heck, 1995), a cross-culturally developed generic multidimensional QOL
measure (WHOQOL group, 1994). This consists of 100 items assessing 24
facets of QOL within six domains (Physical Health, Psychological Health,
Level of Independence, Social Relationships, Environment, and Spirituality/
Religion/Personal Beliefs) and a general evaluative facet (Overall Quality of
Life and General Health) (WHOQOL group, 1995). Each facet is represented
by four items. The response scale is a 5-point Likert scale. Scores on each
facet and domain may range from 4 to 20. The reliability and validity of the
instrument are high (De Vries & Van Heck, 1997).
In addition, the participants were asked to complete a symptom checklist.
They needed to indicate whether they experienced any of 12 physical symp-
toms such as fatigue, arthralgia, cough, muscle pain and weakness, and chest
pain. Finally, subjects were requested to answer questions concerning use of
medication.
Statistical Procedure
Data are expressed as mean SD. In order to detect statistically signifi-
cant differences data were analysed using Student t-tests, Chi-square tests,
loglinear analyses, and ANCOVA, unless stated otherwise. Covariates were
age, marital status, use of corticosteroids, and symptoms. A p-value < .01 was
considered to be statistically significant, unless stated otherwise. All analyses
were performed using the Statistical Package for Social Sciences (SPSS).
RESULTS
Demographic and medical data are summarized in Table 1. The results
indicated that more women than men reported symptoms (χ2 (1, N = 961) =
5.6, p < .05) and that women were on average older (t (848.67) = 3.1, p <
.005). With regard to marital status, it appeared that more men than women
were living together with a partner (χ2 (1, N = 971) = 8.5, p < .005). In
addition, when age and marital status were entered as covariates, women also
appeared to report more symptoms than men (F (1, 947) = 20.5, p < .001).
The duration of the illness (chronicity) was not related to gender, experi-
encing symptoms, or the number of symptoms.
Looking at the type of current symptoms reported, it appeared that women
complained of starting problems, fatigue, skin problems, chest, abdominal,
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TABLE 1. Summary of Reported Symptoms, Listed Medications, and Demo-
graphic Characteristics of the Sarcoidosis Population Studied. Male (n = 358)
and Female (n = 617) Respondents Are Presented Separately
Females (%) Males (%) 2 p <
Symptoms
Muscle pain 271 (44.7) 124 (34.8) 3.2 ns
Chest pain 202 (33.3) 74 (20.8) 12.1 0.001
Abdominal pain 91 (15.0) 28 (7.9) 11.4 0.001
Arthralgia 367 (60.5) 162 (45.5) 19.8 0.001
Muscle weakness 150 (24.7) 76 (21.3) 0.5 ns
Starting problems 235 (38.7) 97 (27.2) 14.8 0.001
Fatigue 469 (77.3) 251 (70.5) 7.3 0.01
Reduced exercise
capacity 331 (54.5) 181 (50.8) 1.1 ns
Erythema nodosum 122 (20.1) 49 (13.8) 6.7 0.01
Heart complaints 67 (11.0) 32 (9.0) 0.1 ns
Eye problems 187 (30.8) 88 (24.7) 2.3 ns
Dry mouth 117 (19.3) 42 (11.8) 3.1 ns
Dyspnea 463 (75.0) 247 (69.0) 3.1 ns
Cough 200 (32.4) 100 (27.9) 1.1 ns
Medication
Eye drops 171 (29.4) 64 (18.8)
Oral steroids 337 (57.7) 222 (65.5)
Heart medication 55 (9.4) 34 (10.1)
Pain killers 240 (41.1) 88 (26.0)
Psychological/
neurological
medication 82 (14.0) 37 (10.5)
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TABLE 1 (continued)
Females (%) Males (%)
Non-steroidal
anti-inflammatory
drugs 236 (40.4) 86 (25.4)
Bronchodilators 185 (31.7) 106 (31.3)
Demographic information Total group
Age range 16-74 21-71 16-74
mean SD 47.7 123 45.4 10.2 46.7 11.6
Years since
diagnosis 11.7 10.6 13.0 11.4 12.2 10.9
Smoking/non-
smoking/missing 30/550/37 17/313/28 47/863/65
Living with partner/
alone/missing 490/123/4 312/46/0 805/174/4
Note. Loglinear analyses with gender for each symptom (age and marital status as
covariates). ns = not significant.
and joint pain more often than men (see Table 1). Subsequently, the patient
group was divided into two groups: a group with current symptoms and a group
without current symptoms. In the patient group experiencing current symptoms,
more females than males reported using eye drops (χ2 (1, N = 829) = 12.4, p <
.001), pain killers (χ2 (1, N = 831) = 21.5, p < .0001), and non-steroidal
anti-inflammatory drugs (NSAIDs) (χ2 (1, N = 831) = 21.4, p < .0001) whilst
males more often used oral steroids (χ2 (1, N = 831) = 5.5, p < .05). In addition,
female patients more often received treatment other than medication, e.g., phys-
iotherapy (χ2 (1, N = 797) = 10.0, p < .005). In the patient group experiencing
no current symptoms, females reported a more frequent use of psychological/
neurological medication (χ2 (1, N = 79) = 5.2, p < .05).
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Within the group of patients not using corticosteroids, female sarcoidosis
patients reported more arthralgia (χ2 (1, N = 363) = 5.6, p < .05) and
erythema nodosum (χ2 (1, N = 363) = 17.1, p < .0001). In the patient group
using corticosteroids, a large number of symptoms were reported more by
female than male patients (see Table 2). Furthermore, male patients who used
corticosteroids reported more reduced exercise capacity and less arthralgia,
muscle weakness, starting problems, muscle pain, and heart problems than
those males who did not use oral steroids (see Table 2). Within the group of
female patients, using corticosteroids was related to increased eye problems
(χ2 (1, N = 578) = 5.2, p < .05), reduced exercise capacity (χ2 (1, N = 578) =
6.1, p < .01), and cough (χ2 (1, N = 573) = 8.4, p < .005).
Analyses concerning QOL scores revealed that men scored higher than
women in the domains of Physical Health and Psychological Health and men
were more satisfied with their quality of sleep and their physical appearance.
Moreover, they indicated a higher sense of mobility and capacity to perform
daily activities. Women reported experiencing more pain but had more posi-
tive feelings (see Table 3). No significant differences emerged in the domains
Social Relationships, Environment, and Spirituality/Religion/Personal Be-
liefs.
The QOL of respondents using corticosteroids was lower on the global QOL
and health facet (t (830.73) = 3.26, p < .005), the domain Level of Independence
(t (907) = 4.98, p < .001), and the facets Energy and Fatigue (t (907) = 2.95, p <
.005), Dependence on Medication or Treatments (t (906) = 7.53, p < .001),
and Working Capacity (t (903) = 3.88, p < .001). Within the group of male
sarcoidosis patients, differences were found only for the domain Level of Inde-
pendence (t (327) = 2.70, p < .01) and its facets Dependence on Medication or
Treatments (t (328) = 4.08, p < .001) and Working Capacity (t (260.60) =
2.70, p < .01). In all instances, those male patients who used corticosteroids had
lower QOL scores. Between female sarcoidosis patients who did and did not use
corticosteroids more QOL differences emerged. At domain level, female patients
using corticosteroids had lower scores on Physical Health (t (573) = 3.66, p <
.001) and Level of Independence (t (571) = 4.73, p < .001). At facet level, six
differences between female sarcoids who did or did not use corticosteroids were
observed. Females who used oral steroids had lower QOL scores on the global
QOL and health facet (t (572) = 3.26, p < .005), Energy and Fatigue (t (571) =
3.48, p < .005), Bodily Image and Appearance (t (554.13) = 3.22, p < .005),
Mobility (t (574) = 3.10, p < .005), Dependence on Medication or Treatments
(t (569) = 6.47, p < .001), and Working Capacity (t (568) = 3.45, p < .005).
Since it is known from a previous study (Wirnsberger, De Vries, Breteler
et al., 1998) that current symptoms are negatively related to QOL, the differ-
ences between female and male patients within the sarcoidosis groups and
with or without current symptoms were examined separately. The results
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TABLE 2. Differences in Symptom Reporting Between Females and Males
Using Corticosteroids and Between Males Using or Not Using Corticosteroids
(Chi-square tests)
Symptoms Using corticosteroids 2 p <
Females (%) Males (%)
Muscle pain 139 (41.9) 65 (29.4) 8.8 0.005
Abdominal pain 44 (13.3) 14 (6.3) 6.8 0.01
Arthralgia 195 (58.7) 85 (38.5) 21.8 0.00001
Starting problems 125 (37.7) 52 (23.5) 12.2 0.001
Fatigue 288 (86.7) 170 (76.9) 9.0 0.005
Erythema nodosum 131 (39.5) 44 (19.9) 23.4 0.00001
Heart complaints 43 (13.0) 14 (6.3) 6.3 0.05
Eye problems 139 (41.9) 65 (29.4) 8.8 0.005
Dyspnea 280 (85.6) 163 (75.8) 8.4 0.005
Cough 211 (63.9) 110 (50.5) 9.8 0.005
Males
No corticosteroids Corticosteroids
Muscle pain 48 (41.0) 65 (29.4) 4.6 0.05
Arthralgia 64 (55.2) 91 (41.2) 7.4 0.01
Muscle weakness 32 (27.6) 41 (18.6) 6.4 0.01
Starting problems 43 (36.8) 52 (23.5) 6.6 0.01
Reduced exercise
capacity 47 (40.2) 117 (52.9) 5.0 0.05
Heart complaints 16 (13.7) 14 (6.3) 5.1 0.05
showed that no differences between male and female sarcoidosis patients
emerged in the group without any current symptoms. In contrast, the gender
differences reported for the total sarcoidosis group also emerged for the
sarcoidosis group with current symptoms, with the exception of the domain
score Psychological Health (see Table 3).
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TABLE 3. Differences in QOL Between Male (n = 300) and Female (n = 541)
Sarcoidosis Patients with Current Symptoms
Female Male
patientsa patientsa F p <
Physical Health 11.7 (2.4) 12.4 (2.5) 13.4 0.001
Pain and Discomfort 12.2 (2.7) 11.5 (2.9) 10.1 0.005
Sleep and Rest 13.8 (3.9) 14.7 (3.8) 9.0 0.005
Psychological Health 13.8 (2.2) 14.2( 2.1) 7.5 0.01
Positive Feelings 13.9 (2.4) 13.4 (2.3) 6.9 0.01
Bodily Image and
Appearance 14.9 (3.7) 16.5 (3.1) 41.4 0.001
Level of Independence
Mobility 13.7 (3.5) 14.5 (3.5) 7.9 0.01
Activities of Daily Living 12.2 (3.3) 13.0 (3.3) 10.0 0.005
Note: Domains are printed in italics. Analyses of covariance (covariates: age, marital status,
symptoms, and use of corticosteroids).
aValues represent mean scores.
DISCUSSION
The aim of this study was to examine gender differences regarding symp-
toms and QOL of sarcoidosis patients. Gender appeared to be related to the
presence of symptoms, the number of symptoms, and in some cases to the type
of symptoms reported by sarcoidosis patients. Concerning the type of symp-
toms, women reported more erythema nodosum, starting problems, fatigue,
arthralgia, chest and abdominal pain. These results are consistent with trends in
the general population that women report more symptoms (Ritchey et al.,
1991) and are more emotionally expressive (Edwards, Nazroo & Brown,
1998). It is tempting to speculate that men and women cope differently with
symptoms. This view is supported by a study amongst women who received
coronary artery bypass surgery. They appeared to attend to different symptoms
and signs as cues to resuming activity during recovery and rehabilitation than
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men (Hawthorne, 1993). Future research should focus on gender differences in
seeking medical aid and the attendance to symptoms in more depth.
Female sarcoidosis patients with current symptoms more often reported
the use of eye drops, pain killers, and NSAIDs. The prescription of NSAIDs
is consistent with the symptoms reported by female sarcoidosis patients.
Moreover, female patients experiencing no current symptoms reported a more
frequent use of psychological or neurological medication compared to male
patients. This phenomenon could not be explained by differences in reported
neurological or psychological problems. Male sarcoidosis patients more fre-
quently used oral steroids. This could not be explained by a difference in
presenting symptoms between male and female patients. Furthermore, Wirns-
berger, De Vries, Wouters et al. (1998) also did not find a relationship between
reported symptoms and the use of corticosteroids. It is possible that male
patients are prescribed corticosteroids in order to accelerate their return to
work. In contrast with the present results, Drent and colleagues (1998) reported
no gender differences regarding the use of corticosteroids.
The QOL of sarcoidosis patients using corticosteroids was lower than
patients who did not use oral steroids in a number of areas. In the literature
(e.g., Mitchell & O’Keane, 1998), a positive relationship was found between
the use of corticosteroids and depression. It is possible that a more negative
outlook on QOL in a number of areas is a reason for pulmonary physicians to
prescribe oral steroids. However, this does not explain the fact that more
QOL differences could be demonstrated in female patients compared with
male patients, irrespective of the use of corticosteroids.
In the present study, gender played a role in a number of QOL domains
and facets. Differences emerged in the physical and psychological domains.
More specifically, differences were found for pain, sleep, positive feelings,
bodily image, mobility, and daily life activities. In all these areas, QOL was
more impaired in females compared to males. The number of QOL differ-
ences was much greater in the present study than in the population of 64
sarcoidosis patients studied by Wirnsberger, De Vries, Breteler et al. (1998).
Using the WHOQOL-100, the same gender difference was found solely with
regard to sleep. However, the sample size of their study population was much
smaller, and more importantly, the majority of the sarcoidosis patients were
male.
More female than male sarcoidosis patients reported symptoms. More-
over, female patients with symptoms had a lower QOL in a number of areas.
The importance of current symptoms for patients’ QOL and health status has
already been established in previous studies (De Vries, Drent, Van Heck, &
Wouters, 1998; Leidy & Traver, 1995; Wirnsberger, De Vries, Breteler et al.,
1998). However, from the present study it became clear that a patient’s
gender is crucial in determining QOL.
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A difference in physical and psychological burden might explain the gen-
der differences in symptoms and QOL. However, female patients did not
experience more life events than males (data not shown). In addition, female
and male sarcoidosis patients did not differ in illness duration or absence
from work through illness (data not shown). It may well be that female
patients experience more difficulties when combining domestic activities
with working outside the home. Furthermore, domestic chores may be more
physically demanding than, for instance, administrative work. Further re-
search into these possible causes of the gender differences is needed.
The present study has a number of limitations which are mainly related to
subject selection. The patients in the present study appeared to suffer from
chronic sarcoidosis and a high percentage of them indicated having one or
more physical symptoms. This might suggest that sarcoidosis patients decide
to become members of the patient organisation when the disease is chronic
and they are experiencing symptoms. Confronted with the disease patients
may need more information about its many different aspects then persons
with transitory sarcoidosis. Another factor may be that patients who live
alone seek contact with other patients through the organisation. Furthermore,
the members who did not participate in the present study (42%), might not
experience symptoms. Unfortunately, this idea cannot be checked within the
present study since there is no information available regarding the occurrence
of symptoms in the non-response group. In the present study, twice as many
female than male patients participated. There are probably also more female
than male patients in the overall sarcoidosis population (e.g., DuBois, 1995),
but exactly how many more is unknown, because there is no chest radiograph
screening program in The Netherlands. In addition, based on the existing
literature, it is difficult to identify which factors determine male and female
participation in research. A possible factor may be that sick females are more
inclined than sick males to participate in studies. However, this remains
speculative. Concerning these limitations, the outcome of the present study
must not be overgeneralised. However, in a previous study (De Vries et al.,
1998) a group of sarcoidosis hospital outpatients were compared with a group
of DSS members. Results showed that when groups were matched for age,
gender, and current symptoms, differences in the vast majority of QOL facets
were absent. The gender differences observed in the members of the DSS
who participated in the present study cannot be ignored as the vast majority
of the respondents reported visiting a pulmonary physician on a regular basis
which may demand more time and effort on the physician’s part (data not
shown).
It is possible that sarcoidosis may behave differently in female and male
patients. If this is true, this may account for the gender differences with
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regard to symptoms. However, as far as the authors know this has not yet
been studied.
In conclusion, male and female sarcoidosis patient members of the DSS
experienced different current symptoms and QOL. Female patients reported
the presence of more symptoms more often and the nature of these symptoms
also differed from those of male patients. In addition, female patients had a
lower QOL in the areas of physical and psychological health, particularly
with regard to pain, sleep, positive feelings, self-esteem, bodily image, mo-
bility, and daily life activities. When the group was divided according to
whether or not symptoms were present, no gender differences emerged with-
in that patient group where symptoms were absent. Medication also differed
between female and male patients. In patients with current symptoms females
were prescribed more eye drops, pain killers, and NSAIDs, whilst males
received more frequently corticosteroids. Future studies should focus on the
different experience of the disease between male and female patients more
extensively. Studies are needed to evaluate whether the differences in the
present study between male and female sarcoidosis patients are caused by a
subject selection bias or life style differences; have a genetic, hormonal or
biological base; or just are an epiphenomenon. Studying gender differences
should facilitate discovery of ways to avoid and treat current and future
health problems (cf. Baum & Grunberg, 1991).
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